(S)-1-Methyl-2-(piperidinomethyl)pyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-1-Methyl-2-(piperidinomethyl)pyrrolidine
• 英文别名: 1-[(1-methylpyrrolidin-2-yl)methyl]piperidine
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.31
• InChiKey: VCVPSRADUBPOKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Preparation of 4-substituted-2-buten-4-olides from mucohalic acids
  申请人：Angell Paul

  公开号：US20060004211A1

  公开（公告）日：2006-01-05

  Methods and materials for preparing 4-substituted-2-buten-4-olides are disclosed. The method includes reacting a mucohalic acid with a silyl enol ether or a ketene silyl acetal in the presence of a Lewis acid.

  披露了制备4-取代-2-丁烯-4-内酯的方法和材料。该方法包括将一个粘酸与一个硅基烯醇醚或一个硅基酮缩酮在路易斯酸的存在的条件下进行反应。
• COLORED COMPOSITION
  申请人：WAKO PURE CHEMICAL INDUSTRIES, LTD.

  公开号：US20160040013A1

  公开（公告）日：2016-02-11

  The present invention is to provide a colored composition having higher heat resistance compared with conventional colored compositions. The present invention further relates to: “a polymer having a monomer unit derived from a monomer which has (i) a cationic rhodamine derivative having, as an counter anion, an anion including an aryl group having an electron-withdrawing substituent and an anion group and (ii) an ethylenically unsaturated bond”, “a monomer which has (i) a cationic rhodamine derivative having, as an counter anion, an anion including an aryl group having an electron-withdrawing substituent and an anion group and (ii) an ethylenically unsaturated bond”, “a colored composition comprising the above-described polymer or the monomer”, and “a colored composition for a color filter comprising the above-described polymer or the monomer”.

  本发明提供了一种具有比传统彩色组合更高耐热性的彩色组合。本发明还涉及：“具有源自具有（i）带有阴离子的阳离子罗丹明衍生物，所述阴离子包括具有电子吸引取代基的芳基和阴离子基团以及（ii）烯丙基不饱和键的单体单体单元的聚合物”，“具有（i）带有阴离子的阳离子罗丹明衍生物，所述阴离子包括具有电子吸引取代基的芳基和阴离子基团以及（ii）烯丙基不饱和键的单体单体单元的单体”，“包括上述聚合物或单体的彩色组合”，以及“用于彩色滤光片的彩色组合，包括上述聚合物或单体”。
• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• Carbamoyl-Substituted Spiro Derivative
  申请人：Jitsuoka Makoto

  公开号：US20080171753A1

  公开（公告）日：2008-07-17

  A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R 6 represents a lower alkyl, etc; and R 7 and R 8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

  化合物的化学式为(I):[其中X、Y、Z和W各自独立地表示可选择性取代的甲烷基；A、B和D各自独立地表示—C(O)—等；Q表示甲烷基或氮；R表示化学式(II-1)，可选择性地取代较低的烷基等；(其中R6表示较低的烷基等；R7和R8各自独立地表示较低的烷基等)]或其药学上可接受的盐。这些化合物和盐对组胺H3受体具有拮抗活性或反向激动活性。它们可用于预防或治疗代谢性疾病、循环系统疾病或神经疾病。
• AZA-SUBSTITUTED SPIRO DERIVATIVES
  申请人：Jitsuoka Makoto

  公开号：US20120149703A1

  公开（公告）日：2012-06-14

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）或其药学上可接受的盐的化合物： 其中X、Y、Z和W各自独立地表示一个甲基基团或氮原子，前提是X、Y、Z和W全部都是甲基基团的情况除外；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示一个甲基基团或氮原子；R表示以下式子（II-1）所表示的基团（其中R6、R7和R8各自独立地表示低级烷基或类似物）。